Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies

Z. Steven Pavletic, Michael R. Bishop, Stefano R. Tarantolo, Salvador Martin-Algarra, Philip J. Bierman, Julie M. Vose, Elizabeth C. Reed, Thomas G. Gross, Jeff Kollath, Khalliq Nasrati, John D. Jackson, James O. Armitage, Anne Kessinger

Research output: Contribution to journalArticle

125 Scopus citations

Abstract

Purpose: To compare hematopoietic recovery, duration at hospitalization, and 100-day survival in patients who received allogeneic-blood stem cells (BSC) or conventional allogeneic bone marrow transplantation (BMT). Patients and Methods: From December 1994 to August 1995, 21 patients participated in a phase II study of allogeneic BSC transplantation. Cells mobilized with granulocyte colony-stimulating factor (G-CSF; 5 μg/kg/d) were collected from human leukocyte antigen (HLA)-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. G-CSF (10 μg/kg/d) was administered posttransplant. The outcomes were compared with 22 identically treated historical patients who received allogeneic BMT. Results: The median infused CD34+ cell and granulocyte-macrophage colony-forming unit (CFU-GM) content were 7.73 x 106/kg and 41.6 x 104/kg, respectively. The median time to a neutrophil count greater than 500/μL was 11 days after BSC and 16.5 days after BMT (P = .0003). A trend toward faster platelet and RBC recovery after BSC was observed. BSC patients received fewer platelet transfusions: 10 versus 19 (P = .015). The median length of hospitalization was shorter after BSC transplantation: 25 versus 31.5 days (P = .0243). The 100-day survival rates were similar: 83% after BSC and 75% after BMT (P = .3585). The incidence of acute GVHD grade II to IV was 57% and 45% for BSC and BMT, respectively (P = .4654). Conclusion: In comparison to BMT, allogeneic BSC transplantation may result in faster hematopoietic recovery, shorter hospital stay, and similar early survival. Whether allogeneic BSC are superior to bone marrow needs to be determined in randomized trials.

Original languageEnglish (US)
Pages (from-to)1608-1616
Number of pages9
JournalJournal of Clinical Oncology
Volume15
Issue number4
DOIs
StatePublished - Apr 1997

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this